◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral OPTIONAL-ADD LOW

3-n-Butylphthalide (NBP)

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD LOW

For Dylan's MMA subconcussive prophylaxis use case, mechanism is highly aligned (oral analog of cerebrolysin's neurotrophic logic — multi-target neuroprotection, mitochondrial preservation, anti-neuroinflammatory) but evidence base is **acute ischemic stroke and post-stroke cognitive impairment in Chinese populations**, not subconcussive impact in young healthy athletes. TBI rodent data is positive but no human TBI RCT exists. Hepatotoxicity signal (ALT elevation 1.4-17.5% in trials) is real but manageable with monitoring + NAC (already in V4). Verdict would upgrade to STRONG-CANDIDATE if (a) any human TBI/concussion RCT reads out positive, (b) CSPC's US Phase 3 program publishes a non-Chinese cohort, or (c) a head-to-head against cerebrolysin shows non-inferiority. For now: cheaper oral adjunct to cerebrolysin worth a single 90-day cycle when the V5 stack is otherwise stable.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    OPTIONAL-WITH-CAVEATS

    / LOW confidence. - Mechanism is highly aligned with the MMA subconcussive prophylaxis thesis (multi-target neuroprotection, mitochondrial preservation, anti-neuroinflammatory). It's the oral analog of the cerebrolysin angle. - But the entire clinical evidence base is Chinese stroke / dementia populations, not young athletes with subconcussive impact. TBI rodent data is positive but no human TBI RCT exists. - Cerebrolysin remains the higher-confidence brain-protection anchor for Dylan. NBP is the cheaper, oral, lower-evidence adjunct/alternative — worth a single 90-day pilot once cerebrolysin baseline is established and bloodwork is clean. - Hepatotoxicity signal (1.4-17.5% ALT elevation) is real but manageable — NAC in V4 is mechanistically protective. - Verdict timing: not in V5 launch; consider for V6 review (Q4 2026) after cerebrolysin first cycle complete.

  • 30-50, executive maintenance
    OPTIONAL-WITH-CAVEATS

    - Stronger case if there's family history of stroke / vascular cognitive decline, vascular risk factors (hypertension, hyperlipidemia), or occupational neuro-stress. The vascular cognitive impairment evidence (B-tier, multiple RCTs) is the demographic match. - For typical executive without vascular risk: cheaper interventions (omega-3, exercise, blood-pressure control, sleep) come first; NBP is a layer above those.

  • 50+, mild cognitive decline / vascular cognitive impairment / post-stroke
    STRONG-CANDIDATE

    in China; OPTIONAL-WITH-CAVEATS in Western context. - This is the on-label, evidence-supported population. EBMCI 2024 (n=270, 12-month, ADAS-cog −2.04 vs placebo) is a clean signal in MCI. PSCI evidence is multi-trial. VCIND evidence solid. - In China: established Rx pathway, well-monitored. Outside China: gray-import logistical friction, no local clinician oversight, hepatic monitoring requires self-arrangement. Strong candidate but operationally complex. - Combine with cerebrolysin for additive clinical benefit (different mechanism); idebenone overlap is well-documented.

  • Anxiety-prone
    NEUTRAL

    No anxiogenic or anxiolytic effect documented. No reason to add for anxiety; no reason to avoid.

  • High athletic load, tested status (WADA-relevant)
    OPTIONAL-WITH-CAVEATS

    - NBP is not on WADA Prohibited List as of 2026. Verify before any sanctioned competition. - Same evidence concern as Dylan-archetype — mechanism is interesting but no athlete RCT. The Chinese stroke evidence does not transfer cleanly to performance settings. - Hepatic monitoring is a real cost in a tested athlete (drug-test panel sees liver enzymes; explanations needed if elevated).

  • Sleep-disordered
    NEUTRAL

    No sleep effect documented. AM-or-midday dosing is fine; no insomnia risk.

  • Recovery-focused (post-injury, post-illness)
    OPTIONAL-ADD

    if neurologic. - For documented concussion / mild TBI, mechanism is favorable and rodent TBI data is encouraging. Practical use case: post-concussion cycle of 60-90 days alongside cerebrolysin, with hepatic monitoring. - Not an indication for non-neurologic recovery (peripheral injuries, post-surgical) — no mechanism advantage there.

  • Strength/anabolic-focused
    SKIP-FOR-NOW

    (wrong category). Not anabolic, not the right tool for strength/mass goals.

▸ Subjective experience (deep)

Even more subtle than cerebrolysin. This is the honest report from the small Western research-chem community + extrapolation from clinical trials in healthy-control arms (where stroke/dementia symptoms aren't being tracked, but side effects are):

  • Acute (first dose, hours): Generally nothing. Mild GI awareness possible (oily celery-derived softgel). No stim, no sedation, no mood shift.
  • Days 1-7: Most users report nothing distinguishable from placebo. Some describe a vague "headedness" or mild headache day 1-3 (rare, dose-dependent).
  • Weeks 2-6: Cumulative — a small fraction of users describe "subtle clarity," "less mental fatigue at end of long workdays," "easier word retrieval." Most describe no perceptible change. Effects are inferential ("I'm taking it for the mechanism, I don't really feel it") rather than felt.
  • Post-cycle: No withdrawal. Effects (if any) fade over 2-4 weeks of tissue washout.
  • What it does NOT feel like: Not a stimulant, not a mood enhancer, not a focus drug, not anxiolytic. If a user reports strong felt effects on NBP at 200-400 mg/d, suspect placebo or stack effect.

Honest expectation-setting for Dylan: Treat NBP as quiet insurance like astaxanthin. The subjective signal is weaker than cerebrolysin's "post-cycle clarity" reports and far weaker than modafinil. Value is in mechanism not feeling. If you cycle NBP for 90 days and "feel nothing," that's the expected modal experience — judge by biomarkers (NfL, ALT) and the absence of subconcussive accumulation rather than by daily subjective.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Minimal in the receptor sense (no DA / 5-HT downregulation pathway). However, sustained CYP3A4 induction by the metabolite chain may modestly autoinduce metabolism over weeks (analogous to many lipophilic small molecules); not extensively studied.
  • Recommended cycle: 60-90 days on, 30-60 days off, especially for prophylactic / non-acute use. Clinical use is often continuous (90-day post-stroke courses; 12-month MCI in EBMCI), but the safety profile in those long-duration trials is what informs the ALT-monitoring guidance, not a "safer when continuous" claim.
  • Reset protocol: If discontinuing, no taper required. ALT/AST should normalize within 2-4 weeks if any elevation occurred. Recheck LFTs 4 weeks post-cycle.
▸ Stacking deep dive

Synergistic with

  • cerebrolysin — Different mechanisms, both neuroprotective; cerebrolysin = peptide-mimetic neurotrophic surge (BDNF/NGF/GDNF axis, IM cycled), NBP = small-molecule mitochondrial / Nrf2 / anti-platelet (oral continuous). Theoretically additive — cerebrolysin builds the neurotrophic infrastructure, NBP keeps the cellular energy / antioxidant / inflammation environment optimal for it. No human RCT comparing or combining the two, but the mechanism breadth is complementary, not redundant. Top-line stack rationale for Dylan if both are pursued.
  • NAC (already in V4 at 1200 mg/d) — Hepatoprotective via glutathione replenishment. This is the single most important co-administration: NBP's hepatotoxicity is GSH-depletion-driven; NAC restores GSH; clinical use of NAC + NBP has been explicitly proposed in pharmacology literature (Drug Metab Pharmacokinet 2021). Keep NAC throughout NBP cycle.
  • curcumin / curcumin phytosome (already in V4) — Anti-neuroinflammatory + anti-oxidative + Nrf2 activator; layered with NBP's Nrf2 activation; phytosome formulation has hepatoprotective signal in animal models. Synergistic.
  • astaxanthin (V5 add) — Lipid-soluble Nrf2 activator + mitochondrial membrane stabilizer; layered antioxidant coverage with NBP. Synergistic.
  • idebenone — BBB-crossing CoQ10 analog; shores up the electron-transport-chain side while NBP supports mitochondrial biogenesis (PGC-1α) and dynamics (Mfn1, Drp1). Combined NBP + idebenone retrospective cohort in vascular dementia (PMC10906564) suggests additive clinical benefit.
  • citicoline (already in V4) — Membrane phospholipid substrate + cholinergic support; complements NBP's neuroprotection-of-existing-cells with materials for membrane repair.
  • omega-3 / DHA (already in V4 at 2 g) — Anti-inflammatory + neuronal membrane fluidity; standard neuroprotection foundation.
  • semax / n-acetyl-semax-amidate — Russian peptides hitting BDNF / neurotrophic axis intranasally; mechanism-complementary to NBP's mitochondrial/anti-inflammatory.
  • PS (phosphatidylserine) (already in V4) — Membrane substrate + cortisol modulator; neutral-to-synergistic.

Avoid stacking with

  • Strong CYP3A4 inducers — rifampicin, St. John's wort, carbamazepine, phenytoin. Amplify hepatotoxic metabolite burden (rifampicin co-administration in vitro confirmed increased toxicity). None are in Dylan's stack.
  • Heavy alcohol load — additive hepatic stress + ADH metabolism overlap. Dylan is alcohol-zero, non-issue.
  • Other hepatotoxic drugs — acetaminophen at high doses (not relevant for Dylan), isoniazid, statins (case-by-case; not a hard contraindication but more frequent LFT monitoring).
  • Strong antiplatelet/anticoagulant therapy (warfarin, DOAC, dual-antiplatelet) — additive bleeding risk theoretically; no significant BAST signal. Not relevant for Dylan.

Neutral / safe co-administration

  • All V4 daily core supplements (Mg, D3+K2, magnesium threonate, theanine, glycine/tryptophan, beta-alanine, vitamin C, rhodiola)
  • Modafinil (mild CYP3A4 inducer — modest theoretical concern, but BAST cohorts include patients on multiple meds; not a documented interaction). Worth flagging: when both modafinil and NBP are running, the modafinil-induced CYP3A4 baseline shifts more NBP through the toxic 3-OH-NBP pathway. Practical mitigation: monitor ALT more often during overlap (week 2 + week 6). Don't pre-emptively skip NBP for modafinil.
  • Bromantane, Adamax/Semax, ALCAR, taurine, apigenin — no documented interactions
  • Creatine, beta-alanine — no interactions
  • BPC-157, TB-500 — no interactions
  • Selegiline at 1-2.5 mg/d — no documented interaction (sub-MAO-A threshold)
▸ Drug interactions deep dive
  • CYP3A4 substrate. NBP is metabolized predominantly by CYP3A4 (also CYP2E1 and CYP1A2 to lesser extent). Strong CYP3A4 inducers (rifampicin, St. John's wort) amplify toxic-metabolite burden. Strong CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit at high intake) would slow NBP clearance and increase parent-drug exposure but reduce toxic metabolite formation — net effect ambiguous, no clinical data. For Dylan: practical concern is modafinil's mild CYP3A4 induction during co-administration — increase LFT monitoring frequency.
  • Alcohol dehydrogenase (ADH). ADH plays a minor role in NBP biotransformation. Heavy alcohol load competes for ADH and increases hepatic oxidative stress. Dylan is alcohol-zero, non-issue.
  • Sulfotransferase 1A1 (SULT1A1). The hepatotoxic metabolite (3-OH-NBP sulfate) is produced by SULT1A1. SULT1A1 polymorphisms (see Pharmacogenomics) modify risk.
  • Antibiotics — gut microbiome modulation. A 2024 PLOS One paper showed that broad-spectrum antibiotic pretreatment alters NBP pharmacokinetics in vivo via microbiome disruption. Magnitude clinically uncertain; relevant if Dylan ever takes a course of antibiotics during NBP cycle — would space the courses if possible.
  • Antiplatelets / anticoagulants. Mild additive bleeding risk theoretically; clinically non-significant in BAST (NBP arm did not have higher hemorrhagic conversion in stroke patients on thrombolysis). Worth flagging for high-risk users.
  • Hormonal contraceptives. No documented interaction; CYP3A4-induced contraceptive failure not a concern at NBP doses (NBP is a substrate, not a strong inducer).
  • Caffeine, nicotine. No interaction.
▸ Pharmacogenomics

NBP pharmacogenomics is minimally characterized in human populations. Theoretical pathways:

  • CYP3A4 polymorphisms (CYP3A4*22, *1B, etc.). Could modify parent-drug clearance and metabolite formation rate. Not clinically validated for NBP specifically.
  • CYP2E1, CYP1A2 polymorphisms. Minor metabolic contribution; theoretical only.
  • SULT1A1 polymorphisms (SULT1A1*2 / R213H). SULT1A1 makes the hepatotoxic 3-OH-NBP sulfate. SULT1A1*2 carriers (~25-35% of European-ancestry populations) have ~50% reduced enzymatic activity — theoretically less toxic metabolite formation, but also potentially altered clearance balance. No human study has stratified NBP outcomes by SULT1A1 genotype. For Dylan post-23andMe: worth pulling SULT1A1 genotype if the channel reports it (not a standard 23andMe variant; might require Promethease / SNPedia lookup).
  • Glutathione-related genes (GSTM1, GSTP1). Glutathione conjugation is the detox pathway for the electrophilic cation. GSTM1-null carriers (~50% of Europeans) have reduced GST capacity — theoretically more vulnerable to the toxic adduct. Combined with NAC supplementation, the practical effect is buffered.
  • Nrf2 (NFE2L2) polymorphisms. Rare variants affect baseline antioxidant gene expression — theoretical interaction with NBP's Nrf2-activation mechanism.
  • APOE ε4. Increases dementia risk; theoretical greater benefit from neuroprotective intervention. Not directly studied for NBP. Worth checking on Dylan's 23andMe (informs broader neuroprotection planning).

Action item post-23andMe: Pull whatever GST / SULT / CYP3A4 / APOE / Nrf2 variants are reported. None will change the decision to trial NBP, but a known SULT1A1*2 / GSTM1-null combination would weakly reinforce NAC co-administration and slightly accelerate the threshold for stopping if ALT trends up.

▸ Sourcing deep dive
Path Vendor Cost (typical) Reliability Notes
Chinese pharmacy (Rx, gray-import) CSPC "Enbipu" 0.1g × 60 caps/box ~$30-60/box retail in China; ~$50-100 with international shipping medium-high Original CSPC product (Shijiazhuang Pharmaceutical, the only approved Chinese manufacturer). 60 caps = 10 days at 600 mg/d, or 20 days at 300 mg/d, or 60 days at 100 mg/d. Authenticity is the concern — Chinese pharmacy gray-import via Taobao agents, Alibaba B2C, or Chinese-diaspora resellers; verify holographic packaging, lot number, expiration. Cost per cycle (90 days at 600 mg/d): $300-600. At 200 mg/d Dylan-protocol: **$30-60/month**.
Research-chem (lab-grade) Cayman Chemical — DL-3-n-butylphthalide CAS 6066-49-5, ≥98% purity $60-150 for 500 mg-1 g depending on size high (lab-tier) Reliable identity + purity (HPLC ≥98%). Sold as research material — not for human use per their TOS. Encapsulation required. Bulk pricing breakdown: ~$0.30-0.60 per 100 mg dose. Practical: weekly fill of dose-counted capsules.
Research-chem Sigma-Aldrich (Millipore-Sigma) — 3-N-Butylphthalide ≥98% HPLC priced by inquiry; typically similar to Cayman high (lab-tier) Same caveat as Cayman. Often requires institutional account; B2C harder than Cayman.
Research-chem MedKoo, MedChemExpress, AdooQ, Smolecule $30-100 for similar quantities medium Similar tier; verify COA. Some have less rigorous purity testing than Cayman/Sigma.
Specialized nootropics vendor Currently none of the major nootropic vendors (Nootropics Depot, Liftmode, etc.) carry NBP as a finished consumer product as of 2026-05 n/a n/a Encyclopedia entry suggests Chinese pharmacy is the practical channel.
Telehealth / Rx (US) Not available (no FDA approval) n/a n/a NBP is not Rx in the US; no telehealth path.
Whole-celery-seed extract (NOT the same product) NOW Foods Celery Seed, SuperSmart "Celery3nb," etc. $10-20/mo high product, wrong content Whole celery-seed extracts contain trace L-3-n-butylphthalide (variable, mg-level per gram) plus many other phthalides and seed compounds. Not equivalent to clinical NBP dosing. Marketing claims of cognitive benefit from celery-seed extracts often invoke NBP research but the L-NBP content per dose is far below clinical doses. Don't use celery-seed extract as an NBP substitute.

Cost math for Dylan's proposed protocol:

  • Pilot cycle: 200 mg/d × 30 days = 6 g total NBP. Cayman 1 g × 6 = ~$300-600, or CSPC 60 × 100 mg caps × 1 box = ~$50-100. Chinese pharmacy is cheaper at this dose.
  • Full cycle: 400 mg/d × 60 days = 24 g total. Chinese pharmacy: ~$150-300 (4 × 60 cap boxes); Cayman research-chem: ~$700-1200. Chinese pharmacy has clear cost advantage at full dose; research-chem is cleaner identity verification.
  • Recommendation: Cayman Chemical for first pilot cycle (purity verification matters most for a compound with hepatotoxicity signal); switch to Chinese pharmacy gray-import once you've confirmed personal tolerance + verified a reliable pharmacy contact.

Quality verification:

  • For Chinese pharmacy product: verify CSPC packaging (holographic stamp), lot/expiry on box, capsule should be amber soft-gel with translucent oil fill (NBP is a clear oily liquid)
  • For research-chem: COA from vendor — HPLC ≥98%, residual solvent within spec, water content <1%, no significant unidentified peaks
  • DL form is the standard Chinese clinical product; pure L-NBP (from Cayman 3413-15-8) is the natural stereoisomer and is also pharmacologically active — both are reasonable
▸ Biomarkers to track (deep)

Baseline (before starting)

  • CBC, CMP — full liver panel (ALT, AST, ALP, GGT, total bilirubin, albumin), kidney function (Cr, BUN, eGFR), electrolytes (already planned for June 2026)
  • Lipid panel, hsCRP, IL-6 — baseline inflammation/vascular markers (already planned)
  • Coagulation panel (PT/INR, aPTT, platelet count) — baseline before any antiplatelet-active compound
  • Serum NfL (neurofilament light) — concussion / axonal damage biomarker; the most informative biomarker for Dylan's MMA brain-protection thesis. Order via specialty lab (Quanterix Simoa platform; LabCorp / Mayo specialty panels).
  • GFAP, S100B — astrocyte injury biomarkers; complementary to NfL.
  • Cognitive baseline — CNS Vital Signs / Cambridge Brain Sciences / similar online battery; document executive function, working memory, processing speed.
  • 23andMe pull (already ordered): GSTM1, GSTP1, SULT1A1, CYP3A4, APOE, Nrf2 — informs hepatotoxicity risk + theoretical response.

During use

  • Week 0, 2, 4, 8 of cycle: ALT/AST + GGT. Stop if ALT >3× ULN.
  • Subjective log: energy, cognition, mood, sleep, GI symptoms, headache, any rash. Daily log for first 2 weeks then weekly.
  • Mid-cycle hsCRP (week 4) — track inflammation response (optional).

Post-cycle (if cycled)

  • Week 4 post-cycle: Repeat LFTs to confirm normalization.
  • Week 6-8 post-cycle: Repeat cognitive battery; compare to pre-cycle.
  • 6-month: NfL trajectory if multi-cycle protocol — track downward trend or stable across cycles vs sparring exposure (the most defensible biomarker signal of subconcussive prophylaxis efficacy).
▸ Controversies / open debates Live debate

  1. Western evidence gap is the central controversy. ~95% of NBP human evidence is from Chinese cohorts, predominantly CSPC-funded or CSPC-adjacent trials. Methodological quality across the meta-analyses is repeatedly flagged as "generally low" (incomplete blinding/randomization reporting). BAST 2023 is the cleanest large trial (publically registered, double-blind, multi-center) and appears methodologically robust, but generalizability outside Chinese populations is genuinely unknown. For Dylan: this is the dominant uncertainty — the use case (MMA subconcussive prophylaxis in a 20yo white male) is two inferential layers removed from the trial population (60-70 year old Chinese stroke patients).

  2. Industry sponsorship. CSPC NBP Pharmaceutical (subsidiary of CSPC Pharmaceutical Group, Shijiazhuang Pharmaceutical) holds the patent and is the only approved Chinese manufacturer. CSPC has funded a substantial fraction of the NBP literature, including BAST. Effect-size inflation by sponsorship bias is a real possibility. Counter: BAST's effect size (OR 1.70) is in line with other Eastern neuroprotection RCTs (citicoline, edaravone) and is not implausibly large.

  3. Mechanism is "everything, therefore nothing"? Like cerebrolysin, NBP's pitch is multi-target — mitochondrial + Nrf2 + NF-κB + Wnt + anti-platelet + anti-apoptotic. Skeptics argue this breadth is unfalsifiable. Counter: phthalides as a chemical class hit multiple cellular stress pathways, and mechanism breadth maps to clinical breadth (stroke + cognitive impairment + TBI rodent). Same argument as cerebrolysin.

  4. Hepatotoxicity tradeoff. Unlike cerebrolysin (peptide, no CYP burden), NBP creates a real hepatotoxic metabolite (3-OH-NBP sulfate → electrophilic cation → covalent protein adducts). Frequency is small-to-moderate (1.4-17.5% ALT elevation), severity usually mild and reversible, but the mechanism is established and the long-term Western safety data is thin. For a 20-year-old taking it prophylactically (not for an active disease), the risk-benefit calculus is more conservative than for a stroke patient. This is a real reason to favor cerebrolysin as the higher-confidence anchor and treat NBP as an adjunct.

  5. Subconcussive impact prophylaxis is unproven (same as cerebrolysin caveat). No human RCT in athletes. Mechanism extrapolation from stroke / TBI rodent data is reasonable but not direct.

  6. Cost-effectiveness. At Chinese-pharmacy gray-import prices, NBP is genuinely cheap ($30-80/mo at Dylan-protocol doses). Research-chem is more expensive ($100-300/mo at full dose) and requires self-encapsulation. Cost per "evidence-quality unit" is favorable vs. some Khavinson peptides but unfavorable vs. cerebrolysin's much stronger TBI evidence.

  7. CSPC US Phase 3 development. CSPC has FDA orphan-drug designation for ALS and IND/Phase activity for stroke. If a Western-cohort Phase 3 reads out positive, the verdict upgrades meaningfully. Watch over the next 1-3 years.

  8. Encyclopedia accuracy flag: The encyclopedia entry (Section 29, line 1040+) describes NBP as a "Strong V5 candidate for brain-priority + MMA impact thesis." This wiki entry explicitly downgrades that to OPTIONAL-WITH-CAVEATS / LOW confidence after deeper research, on the basis that (a) no human TBI RCT exists, (b) the entire clinical evidence base is Chinese stroke/dementia, (c) hepatotoxicity signal demands monitoring, and (d) cerebrolysin is the higher-confidence anchor with overlapping mechanism. The encyclopedia's "hold for V6" framing is consistent with this verdict — V6 review is appropriate, V5 inclusion would be premature.

▸ Verdict change log
  • 2026-05-05 — Initial verdict: OPTIONAL-WITH-CAVEATS (LOW confidence). For Dylan-archetype: mechanism is highly aligned with MMA subconcussive prophylaxis thesis (oral analog of cerebrolysin's neurotrophic logic) but human evidence is exclusively Chinese stroke/dementia populations; no human TBI / subconcussive RCT exists. Cerebrolysin remains the higher-confidence anchor. NBP best positioned as a V6+ adjunct after first cerebrolysin cycle is established and bloodwork (especially LFTs) is clean. Pilot at 200 mg AM × 30 days with bi-weekly ALT monitoring; step up to 200 mg BID × 60 days if tolerated. Keep V4 NAC throughout (mechanistically hepatoprotective). Source via Cayman Chemical for purity-verified pilot, transition to CSPC Chinese-pharmacy gray-import for cost if continuing. Verdict upgrade triggers: (a) any human TBI/concussion RCT reads out positive, (b) CSPC's US Phase 3 publishes a non-Chinese cohort, (c) head-to-head vs cerebrolysin shows non-inferiority, (d) Dylan develops a documented concussion (then NBP becomes part of post-concussion protocol alongside cerebrolysin).
▸ Open questions / gaps Open
  1. No human TBI RCT. All TBI evidence is rodent. A 20-30 year old healthy-athlete subconcussive RCT does not exist. Trial-registry watch: any TBI / concussion-related trial of NBP would change this calculus substantially.
  2. No non-Chinese cohort in published trials. CSPC's US Phase 3 status is "active development" but no published Western-cohort efficacy data as of 2026-05. Generalizability remains the dominant uncertainty.
  3. Optimal prophylactic dose. All dose-finding evidence is in stroke/dementia at 600 mg/d. The 200-400 mg/d "research-chem dose" is community pragmatism without RCT support. Does prophylactic mechanism engagement happen below the clinical dose? Unknown.
  4. Cycle frequency for prophylaxis. Clinical use is often continuous (12-month MCI). For prophylactic use, is 60-90 days on / 30-60 days off optimal, or is continuous low-dose preferable? No data.
  5. Long-term Western safety data. Decades of Chinese clinical use provide a population-level safety signal, but Western pharmacovigilance reporting on long-term NBP is essentially nonexistent. Hepatic adduct cumulative burden over years of cycling is theoretically plausible but unmeasured.
  6. Head-to-head vs cerebrolysin. No direct comparator trial. If NBP is non-inferior, the lower cost + oral route + manageable hepatic monitoring make it competitive. If cerebrolysin is meaningfully superior, NBP remains an adjunct.
  7. Pharmacogenomic stratification. SULT1A1, GSTM1, CYP3A4 polymorphism effects on hepatotoxicity risk are theoretically real but not clinically validated. Post-23andMe stratification would be exploratory.
  8. NBP + cerebrolysin interaction. No human data on co-administration. Theoretically additive, no documented antagonism, no shared pathway that would cause interference. Conservative practice: stagger first exposures.
  9. Concussion-event protocol (open thread for Dylan). If Dylan ever takes a documented concussion, what's the optimal NBP role alongside the immediate-cerebrolysin playbook? Mechanism suggests synergy; no human data; proposal would be 200-400 mg/d × 60-90 days starting within 1-2 weeks of injury, alongside cerebrolysin 10 mL IM × 20 d.
▸ Sources (full, with our context)

Primary RCTs (most important)

Systematic reviews / meta-analyses

Mechanism (2024-2025 — most current)

TBI evidence (rodent — the closest mechanism-extrapolation for Dylan)

Pharmacokinetics + safety

Specific use cases

Sourcing / regulatory

Encyclopedia + community context

Back to compact view